Over the past two decades, besides osimertinib, the primary EGFR-TKI drugs causing cutaneous vasculitis have been the first generation EGFR-TKIs, gefitinib and erlotinib, with a total of 14 cases reported (Table 3). The gene discussed is EGFR; the disease is cutaneous vasculitis.